MDY Mdy Healthcare

RNS No 5871k
MEDISYS PLC
11th December 1997


                                  MEDISYS PLC
                            Annual General Meeting
                              and Trading Update

Medisys  PLC, the medical device company which was admitted to AIM on 28  July
1997, announces that all resolutions put before shareholders were duly carried
at the Annual General Meeting held today in London.

Following  completion of the formal proceedings of the meeting, Chairman,  Mr.
Bill Bruce, made the following statement on developments since the year-end:

"At  the  time  of the announcement of the Company's 1997 Preliminary  Results
last  October,  I stated that the Board was actively engaged  in  seeking  new
technologies and acquisition opportunities for your Company.  I  am  happy  to
report that we are making satisfactory progress on both fronts.

"I  am  also delighted to confirm to shareholders that the NicSafe 1800 needle
disposal system was recently approved for distribution in the United States by
the  US  Food & Drug Administration and is the first and only needle destroyer
to gain FDA approval for clinical use.

"The  US  FDA  is  recognised  as having some of the  most  stringent  testing
procedures  for new medical products anywhere in the world.  As a  results  of
the  approval,  our  product's reputation has been greatly  enhanced.   Recent
changes  in legislation in the US will allow us to advertise the NicSafe  1800
as FDA approved.

"Following FDA approval, we are now progressing toward our product  launch  in
the United States.  Test marketing in selected sites is underway and we expect
to  be  in  a position to commence sales during the first quarter of 1998,  in
keeping with plan.

"I  am  pleased  to  announce that we have entered into an agreement  with  B.
Braun,  the  German  multi-national medical  products  company,  who  will  be
distributing  the NicSafe 1800 in nine Asia Pacific countries.  B.  Braun  has
been  a  customer  of  Hypoguard.  This expanded relationship  represents  the
synergy your Board saw at the time of the acquisition.

"Hypoguard  itself  will  be  introducing two  new  glucose  monitoring  meter
products  this month and early in the new year.  Hypoguard has  a  history  of
innovation  in the diabetic products marketplace, and these new products  will
continue our technological leadership in the field.

"Biocure  research  continues  to  make  encouraging  progress.   We  are   in
discussion with a number of parties with a view to securing funding for future
R & D while retaining significant interest in the outcome for shareholders.

"As  I said at the year-end, Medisys PLC has undergone major changes over  the
past few months, both in management and strategic direction.  The current year
will  be  one of consolidation, new product introductions and growth, and  the
Board looks forward with confidence to a successful outcome".


Enquiries:
Medisys PLC:
Brian Timmons, Finance Director                     0171 436 3353
Binns & Company:
Peter Binns or Paul Vann                            0171 786 9600
                                       
                                       
Editors' Notes:

The  NiC  1800  system - the first product to be launched by the  biohazardous
medical waste division of Medisys - is marketed to healthcare institutions and
private practitioners as a cost-effective way of disposing of used needles and
reducing the incidence of needlestick injuries among healthcare workers.


END

CAGZFFFFDLKZFKX

MDY Healthcare (LSE:MDY)
Historical Stock Chart
Von Jun 2024 bis Jul 2024

MDY Healthcare (LSE:MDY)
Historical Stock Chart
Von Jul 2023 bis Jul 2024